Skip to main content

Table 1 Baseline characteristics of the included studies for MBC

From: A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer

Author + Year Study Capacity (N) Her2 Positive (N) Triple Negative (N) Median/Mean Age Therapy Line Menopausal Status Setting ECOGa
Ibrahim NK 2005 [24] 63 NMb NM 48.2 Mixed Both Pre- and Post- Metastatic 0–1
Gradishar WJ 2005 [19] 454 NM NM 53.1 Mixed Both Pre- and Post- Metastatic 0- ≥ 3
Blum JL 2007 [6] 181 72 28 53 Further Both Pre- and Post- Metastatic 0–1
Guan ZZ 2009 [17] 210 NM NM 50 Further Both Pre- and Post- Metastatic 0–1
Mirtsching B 2011 [29] 72 22 NM 63.5 First NM Metastatic 0–2
Gradishar WJ 2009/2012 [15, 16] 300 NM NM NM First Both Pre- and Post- Metastatic 0–2
Brezden B 2016 [4] 123 NM NM NM First Both Pre- and Post- Metastatic 0–2
Ranade AA 2013 [36] 195 NM NM NM Mixed NM Metastatic 0–2
Palumbo R 2015 [35] 52 0 16 53 Further Both Pre- and Post- Metastatic 0–2
Fabi A 2015 [14] 42 5 8 48 Further NM Metastatic 0–2
Hurria A 2015 [21] 39 NM NM 60 Mixed NM Metastatic 0–1
Andres FT 2015 [1] 64 0 64 51 Mixed NM Metastatic 0–2
Jain MM 2016 [25] 180 NM NM NM Mixed Both Pre- and Post- Metastatic 0–2
Yamamoto S 2017 [42] 35 13 8 59 Mixed Both Pre- and Post- Metastatic 0–2
Tamura K 2017 [39] 197 0 36 NM First NM Metastatic 0–1
Bernardo A 2017 [5] 234 0 51 58 Further NM Metastatic 0- ≥ 2
Gennari A 2018 [18] 255 0 NM 58 First NM Metastatic 0–1
Marschner N 2018 [32] 697 96 96 62.3 Mixed NM Metastatic 0- ≥ 2
Hurria A 2019 [23] 40 NM 10 73 Mixed NM Metastatic NM
Ciruelos E 2019 [7] 60 0 NM NM First NM Metastatic 0–1
Hara F 2019 [22] 141 0 141 NM Mixed NM Metastatic 0–1
Schmid P 2020 [38] 1271 0 1271 NM First NM Metastatic 0–2
  1. aECOG Eastern Cooperative Oncology Group
  2. bNM Not Mentioned